Retrospective Evaluation of Patients With Uveal Melanoma Treated by Stereotactic Radiosurgery With and Without Tumor Resection

Suesskind, Daniela; Scheiderbauer, Jutta; Buchgeister, Markus; Partsch, Michael; Budach, Wilfried; Bartz‐Schmidt, Karl Ulrich; Ritz, Rainer; Grisanti, Salvatore; Paulsen, Frank

doi:10.1001/jamaophthalmol.2013.697

Cited by 24 publications

(24 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The survival strategies in these studies proposed the use of single-dose stereotactic radiotherapy with combined tumor resection. This can increase tumor control with fewer radiation complications than mono-treatment with single-dose stereotactic radiotherapy [30,31].…”

Section: Discussionmentioning

confidence: 99%

Uveal melanoma survival rates after single dose stereotactic radiosurgery

Furdová¹,

Babál²,

Kobzová³

et al. 2018

neo

View full text Add to dashboard Cite

This paper presents the long-term results of single dose stereotactic radiosurgery for intraocular uveal malignant melanoma, and summarizes the results of the retrospective study in 170 Slovak patients. A group of uveal melanoma patients (149 choroidal melanoma, 21 ciliary body melanoma) from 20 to 92 years of age with 59 year median were treated in 2001-2016. There were 81males (47.7%) and 89 females 89 (52.3%). The median overall follow-up time was three years. The median tumor volume at baseline was 0.5 cm3 (ranging from 0.2 to 1.6 cm3). The therapeutic dose was 35.0 Gy by 99% of dose volume histogram. The survival after single dose stereotactic radiosurgery was 96% in one year, 93% in two years, 84% in five years, 80% in seven years and 52% in eleven years. Secondary enucleation was necessary for 22 patients because of secondary glaucoma complication. The enucleation free interval ranged from one to six years. The survival rates in five year intervals and necessity of secondary enucleation due to complications after single dose stereotactic radiosurgery is comparable to other techniques.

show abstract

Section: Discussionmentioning

confidence: 99%

Uveal melanoma survival rates after single dose stereotactic radiosurgery

Furdová¹,

Babál²,

Kobzová³

et al. 2018

neo

View full text Add to dashboard Cite

show abstract

“…Schilling et al [ 16 ] noted 3 cases of secondary enucleation all due to NVG. Suesskind et al [ 18 ] registered higher frequency of enucleation in eyes with ciliary body involvement, LBD > 18 mm and T4 size category. Suesskind et al [ 18 ] reported a significantly lower rate of NVG, RR, and radiation optic neuropathy in ER + GKRS group compared to GKRS only group.…”

Section: Resultsmentioning

confidence: 99%

“…Suesskind et al [ 18 ] registered higher frequency of enucleation in eyes with ciliary body involvement, LBD > 18 mm and T4 size category. Suesskind et al [ 18 ] reported a significantly lower rate of NVG, RR, and radiation optic neuropathy in ER + GKRS group compared to GKRS only group. In the latter, 4 cases of TTS and 12 cases of NVG developed during follow-up, compared to no cases in the ER-treated group.…”

Section: Resultsmentioning

confidence: 99%

Vitreoretinal Surgery in the Prevention and Treatment of Toxic Tumour Syndrome in Uveal Melanoma: A Systematic Review

Romano

Catania

et al. 2021

IJMS

View full text Add to dashboard Cite

Toxic tumour syndrome (TTS) is a particularly aggressive form of secondary vasculopathy occurring after radiation therapy of uveal melanoma due to the persistence of the necrotic tumour mass inside the eye. The development of TTS confers a particularly unfavourable functional and anatomical ocular prognosis, ultimately requiring enucleation in most cases if untreated. Vitreoretinal (VR) surgery has been successfully applied for treatment and prevention of TTS using both resecting and non-resecting techniques. In this systematic review, we aim to define characteristics of uveal melanomas benefiting the most from secondary VR surgery and to outline the optimal type and timing of VR intervention in such cases. Analysis of the literature reveals that endoresection should be performed within 3 months after radiotherapy to tumours thicker than 7 mm and with a largest basal diameter between 8 mm and 15 mm with post-equatorial location, especially after proton beam treatment. Alternatively, endodrainage remains a valid therapeutic option in eyes with macula-off retinal detachment, tumour diameter larger than 15 mm or ciliary body involvement. VR surgery can be successful in the management of TTS following radiotherapy for uveal melanoma when timing and indication are appropriately evaluated.

show abstract

“…Eye-preserving treatments include radiotherapy, local resection, transpupillary thermotherapy, laser photocoagulation or a combination of these [36,37]. Radiotherapy can be applied as plaque brachytherapy, stereotactic irradiation or proton beam radiotherapy and all are effective in achieving local tumor control in most cases [36][37][38][39][40][41][42]. But radiation-associated normal tissue complications can also persist and be severe.…”

mentioning

confidence: 99%

“…Reducing the SRS dose to 40 Gy or less as well as excluding treatment to tumors near the ciliary body can decrease the rate of glaucoma without affecting the rate of tumor control [39]. In another retrospective study of UM patients treated by SRS with and without tumor resection, it was concluded that SRS in combination with tumor resection might be associated with increased tumor control and fewer radiation complications than SRS alone [41].…”

mentioning

confidence: 99%

The Potential Complementary Role of Targeted Alpha Therapy in the Management of Metastatic Melanoma

2015

View full text Add to dashboard Cite

Standard treatments for metastatic melanoma have recently extended survival although many patients still succumb. Targeted alpha therapy (TAT) is a new therapeutic approach in which a cancer-targeting vector is labeled with an alpha-emitting radioisotope. Alpha-particles have the shortest range and highest energy transfer, and produce localized, high-density and lethal ionization damage to DNA. Thus, the targeted radiation can kill isolated cancer cells circulating in blood and lymphatic vessels, regress metastatic cancer cell clusters, and disrupt the vasculature of solid tumors. Preclinical and clinical studies of TAT for metastatic melanoma demonstrate its safety and anti-tumor activity. We recommend ways in which TAT can be used to treat small-volume disease sometimes in conjunction with cytoreductive anti-melanoma therapies.

show abstract

Retrospective Evaluation of Patients With Uveal Melanoma Treated by Stereotactic Radiosurgery With and Without Tumor Resection

Cited by 24 publications

References 38 publications

Uveal melanoma survival rates after single dose stereotactic radiosurgery

Uveal melanoma survival rates after single dose stereotactic radiosurgery

Vitreoretinal Surgery in the Prevention and Treatment of Toxic Tumour Syndrome in Uveal Melanoma: A Systematic Review

The Potential Complementary Role of Targeted Alpha Therapy in the Management of Metastatic Melanoma

Contact Info

Product

Resources

About